|
Immunocore Holdings plc (IMCR): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Immunocore Holdings plc (IMCR) Bundle
Dive into the cutting-edge world of Immunocore Holdings plc, a pioneering biotech company revolutionizing cancer and infectious disease treatment through groundbreaking T cell receptor (TCR) immunotherapies. With their FDA-approved KIMMTRAK therapy for uveal melanoma and a robust pipeline of innovative treatments, Immunocore is transforming precision medicine by leveraging proprietary soluble TCR technology. This comprehensive marketing mix analysis reveals how this dynamic company is strategically positioning itself to deliver breakthrough therapies that could potentially change the landscape of targeted immunological treatments.
Immunocore Holdings plc (IMCR) - Marketing Mix: Product
T Cell Receptor (TCR) Bispecific Immunotherapies
Immunocore specializes in developing precision immunotherapies using proprietary soluble T cell receptor (TCR) technology targeting cancer and infectious diseases.
| Product Category | Technology Platform | Target Diseases |
|---|---|---|
| TCR Bispecific Immunotherapies | Soluble TCR Technology | Oncology, Infectious Diseases |
Flagship Product: KIMMTRAK
KIMMTRAK represents the first FDA-approved TCR therapy, specifically designed for uveal melanoma treatment.
- FDA Approval Date: February 2022
- Indication: Metastatic uveal melanoma
- Unique mechanism targeting gp100 protein
Pipeline of TCR Therapies
| Therapy | Development Stage | Target Disease |
|---|---|---|
| KIMMTRAK | Approved | Uveal Melanoma |
| IMC-C103C | Clinical Trials | Solid Tumors |
Therapeutic Areas of Focus
- Oncology
- Infectious Diseases
- Precision Immunotherapies
Immunocore Holdings plc (IMCR) - Marketing Mix: Place
Global Headquarters and Research Facilities
Immunocore Holdings plc is headquartered in Abingdon, Oxfordshire, United Kingdom. The company maintains critical research and development centers across two primary locations:
| Location | Facility Type | Purpose |
|---|---|---|
| Oxfordshire, United Kingdom | Global Headquarters | Corporate Operations and Primary Research Center |
| Rockville, Maryland, United States | Research and Development Center | Immunotherapy Research and Drug Development |
Market Presence
Immunocore's commercial distribution strategy focuses on:
- North American market
- European pharmaceutical markets
- Select international oncology and infectious disease markets
Strategic Distribution Channels
| Channel | Description | Target Market |
|---|---|---|
| Direct Sales | Specialized oncology treatment centers | United States and European Union |
| Pharmaceutical Partnerships | Collaborative drug development and distribution | Global pharmaceutical networks |
Key Pharmaceutical Collaborations
- GSK (GlaxoSmithKline)
- Genentech
- Eli Lilly
Market Expansion Strategies
Geographic Expansion Focus:
- United States oncology market
- European Union rare disease markets
- Emerging international immunotherapy markets
Immunocore Holdings plc (IMCR) - Marketing Mix: Promotion
Presenting Clinical Data at Major Oncology and Immunotherapy Conferences
In 2023, Immunocore presented clinical data at key conferences including:
| Conference | Date | Key Presentations |
|---|---|---|
| American Association for Cancer Research (AACR) | April 2023 | tebentafusp (IMCgp100) data in metastatic uveal melanoma |
| European Society for Medical Oncology (ESMO) | October 2023 | KIMMTRAK® clinical updates |
Engaging with Medical Professionals through Scientific Publications
Scientific publications in 2023:
- Published 7 peer-reviewed articles in journals like Nature Medicine and Journal of Clinical Oncology
- Cumulative citation index of 42 for T-cell receptor (TCR) therapeutic research
Utilizing Investor Relations and Financial Communications
Investor communication metrics for 2023:
| Communication Channel | Frequency | Reach |
|---|---|---|
| Earnings Calls | Quarterly | Over 150 institutional investors |
| Investor Presentations | 6 major events | Approximately 250 financial analysts |
Leveraging Digital Platforms
Digital communication statistics:
- Website traffic: 78,000 unique visitors in 2023
- LinkedIn followers: 12,500
- Twitter engagement rate: 3.2%
Participating in Biotech Investor Conferences
Conference participation in 2023:
| Conference | Location | Investor Meetings |
|---|---|---|
| J.P. Morgan Healthcare Conference | San Francisco | 42 one-on-one meetings |
| Jefferies Healthcare Conference | New York | 35 investor interactions |
Immunocore Holdings plc (IMCR) - Marketing Mix: Price
Premium Pricing Strategy for Innovative Immunotherapy Treatments
KIMMTRAK (tebentafusp-tebn), priced at approximately $32,000 per month for metastatic uveal melanoma treatment, reflects the company's premium pricing approach for rare cancer therapies.
| Treatment | Annual Cost | Market Segment |
|---|---|---|
| KIMMTRAK | $384,000 | Rare Cancer Immunotherapy |
Competitive Pricing within Rare Cancer Treatment Market
Pricing strategy for KIMMTRAK considers several key factors:
- Unique therapeutic mechanism
- Limited treatment alternatives
- High clinical development costs
- Specialized patient population
Reimbursement Landscape
| Reimbursement Category | Coverage Percentage |
|---|---|
| Medicare | 80% |
| Private Insurance | 70-85% |
Pricing Influenced by Clinical Value
KIMMTRAK's pricing reflects its clinical performance, with median overall survival of 21.7 months compared to 16.0 months in control groups.
Negotiation Strategies
- Value-based pricing model
- Outcome-driven reimbursement discussions
- Tiered pricing for different healthcare systems
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.